MedTour China 30-day visa-free & 240h transit hospital information
A healthcare professional with a stethoscope and a red heart symbol representing cardiology care
Cardiovascular Medicine

China's Wire-Free Revolution: How QFR Technology Is Rewriting the Rules of Coronary Intervention Worldwide

May 29, 2026 · MedTour China

1. The Angiogram That Didn’t Need a Wire

On a Thursday morning in October 2024, a 58-year-old man lay on the catheterization table at Xijing Hospital in Xi’an, China. His coronary angiogram showed a narrowing in the left anterior descending artery — the so-called “widow-maker” vessel. To the naked eye, the stenosis looked somewhere between 50 and 70 percent. That is the grey zone of interventional cardiology: stent it unnecessarily, and the patient carries a permanent metal implant with lifelong antiplatelet medication. Leave it untreated, and the patient may return with a heart attack.

Twenty years ago, the only way to resolve the ambiguity would have been to thread a pressure-sensor wire into the coronary artery — a procedure that adds time, cost (roughly US$600–1,000 per wire), and a small but real risk of vessel injury. In many catheterization labs around the world, and in nearly all of China’s vast network of hospitals outside the elite centers, the wire is simply not available. Cardiologists make a visual estimate and hope for the best.

On this Thursday morning, the Xijing team did something different. They pulled up the patient’s angiogram on a computer screen, drew two points on the image — proximal and distal to the narrowing — and clicked “compute.” Ninety seconds later, a number appeared: 0.73. Below the ischemic threshold of 0.80. The stenosis was functionally significant. The patient received a coronary stent. Eighteen months later, he has had no further events.

The software that produced that number is called QFR — Quantitative Flow Ratio. It was invented in China. It requires no pressure wire, no adenosine infusion, no additional hardware whatsoever. And it has now been validated in a landmark randomized trial published in The Lancet that enrolled nearly 4,000 patients across 26 Chinese hospitals — the largest trial of its kind ever conducted.

Cardiology care with stethoscope and heart symbol

2. What Is QFR? The Chinese Invention That Bypasses the Pressure Wire

To understand why QFR matters, one must first understand how cardiologists decide whether to place a coronary stent.

For decades, the decision was made by eyeball. The interventional cardiologist would inject contrast dye into the coronary arteries, watch the X-ray movie, and estimate the percentage of narrowing. A 70% stenosis got a stent. A 50% stenosis got medical therapy. Everything in between was a coin toss.

In the 1990s, Dutch cardiologist Nico Pijls introduced a radically better method: fractional flow reserve, or FFR. Instead of estimating anatomy, FFR measures physiology. A thin wire with a pressure sensor at its tip is threaded past the narrowing. By comparing the pressure before and after the stenosis under maximal blood flow (induced by adenosine), FFR gives a precise number between 0 and 1. A value below 0.80 means the narrowing is functionally significant — it is actually restricting blood flow — and the patient will benefit from stenting.

FFR revolutionized cardiology. The landmark FAME and FAME 2 trials proved that FFR-guided PCI produces better outcomes than angiography-guided PCI. International guidelines now give FFR a Class I, Level A recommendation. Yet despite this, global FFR utilization remains stubbornly below 15%. The reasons: cost, time, the need for adenosine (which causes unpleasant flushing and breathlessness), and the technical skill required to maneuver the wire.

QFR eliminates all of these barriers. It works entirely from the angiogram — the very images the cardiologist has already acquired as part of the routine catheterization. The software reconstructs the coronary tree in three dimensions from two or more angiographic projections, then applies computational fluid dynamics to simulate blood flow and calculate the pressure gradient. No wire. No adenosine. No additional cost beyond the software license.

QFR was invented by a team of Chinese engineers and physicians led by Dr. Tu Shengxian, a biomedical engineer, and Dr. Xu Bo, a master interventional cardiologist at Fuwai Hospital, the Chinese Academy of Medical Sciences’ National Center for Cardiovascular Diseases in Beijing. Their initial validation studies, published in the Journal of the American College of Cardiology in 2016–2017, showed that QFR correlated with wire-based FFR with an accuracy of approximately 93%. The international cardiology community took notice, but the definitive proof — a randomized outcomes trial — was still needed.

ECG machine displaying heart rate results

3. FAVOR III China: The Trial That Changed Everything

The trial was called FAVOR III China — the third and largest iteration of the Functional Assessment by Virtual Online Reconstruction series. It was designed and led by Dr. Xu Bo at Fuwai Hospital, with Professor Patrick W. Serruys (the Netherlands/Ireland) and other international luminaries serving on the steering committee.

Surgeons performing a delicate procedure

The design was simple and rigorous: 3,847 patients at 26 Chinese hospitals, all with coronary artery disease requiring PCI procedure, were randomly assigned to either QFR-guided PCI or conventional angiography-guided PCI. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE) — a composite of death from any cause, myocardial infarction, and ischemia-driven revascularization — at one year.

The results, published in The Lancet on November 4, 2021, were striking:

  • 35% relative reduction in MACCE at one year: 5.8% in the QFR-guided group versus 8.8% in the angiography-guided group (hazard ratio 0.65; 95% CI 0.51–0.83; p = 0.0004).
  • Fewer stents deployed: QFR guidance led to fewer vessels being treated (1.02 vs. 1.10 per patient), meaning patients in the QFR group received fewer unnecessary stents.
  • Lower myocardial infarction rate: 3.0% vs. 4.5%.
  • Lower revascularization rate: 2.6% vs. 3.8%.

The implications were profound. QFR not only matched wire-based FFR in accuracy — it actually improved outcomes by preventing both undertreatment (missing functionally significant lesions) and overtreatment (stenting insignificant ones). And it did so without any additional hardware, without adenosine, and at a fraction of the time and cost.

The three-year follow-up results, presented at major cardiology conferences in 2024, confirmed that the benefit of QFR-guided PCI was sustained: the separation in event curves between the two groups continued to widen over time, suggesting that the initial decisions made with QFR guidance had durable consequences for patients.

Dr. Gregg W. Stone, the renowned American interventional cardiologist and co-principal investigator of numerous landmark trials, called FAVOR III China “a watershed moment for interventional cardiology” and noted that QFR could “democratize physiology-guided PCI globally.”

4. How QFR Works: From Angiogram to Answer in 90 Seconds

Scientist analyzing data on advanced monitors

The elegance of QFR lies in its computational pipeline, which transforms a standard coronary angiogram — a two-dimensional X-ray movie — into a three-dimensional, physiologically meaningful pressure map. The process has three stages:

Stage 1: 3D Reconstruction

Two angiographic projections of the same coronary artery, acquired at least 25 degrees apart, are fed into the QFR software. Using epipolar geometry and computer vision algorithms, the system reconstructs the vessel lumen in three dimensions. The reconstruction captures not just the diameter at each point along the vessel, but the three-dimensional curvature, which matters because bends create additional resistance to flow.

Stage 2: Flow Velocity Calculation

Instead of injecting adenosine to induce maximal hyperemia (as required for wire-based FFR), QFR employs a technique called contrast-flow QFR (cQFR). The software tracks the speed at which contrast dye travels down the vessel during the angiogram. This contrast transit time serves as a surrogate for coronary flow velocity. Faster transit means higher flow; slower transit suggests downstream resistance.

Stage 3: Pressure Drop Computation

With the 3D vessel geometry and the flow velocity in hand, the software applies computational fluid dynamics — specifically, the Navier-Stokes equations governing fluid flow — to calculate the pressure drop across every segment of the vessel. The result is a QFR value for each stenosis: the ratio of distal pressure to proximal pressure, analogous to the FFR value obtained invasively. The entire computation takes 60 to 90 seconds on a standard workstation.

A QFR value of ≤ 0.80 indicates a functionally significant stenosis that is likely to benefit from revascularization. A value > 0.80 suggests that the narrowing, while anatomically visible, is not restricting flow enough to cause ischemia, and the patient can safely be managed with medical therapy alone.

5. China’s Cardiovascular Clinical Research Engine

Modern medical centre building with glass facade

The FAVOR III China trial did not emerge in isolation. It is the product of a cardiovascular clinical research infrastructure that China has built systematically over the past two decades — an infrastructure that now rivals, and in some respects surpasses, that of any other country.

China has the world’s largest burden of cardiovascular disease by absolute numbers: an estimated 330 million patients, including 11.39 million with coronary heart disease. This creates a patient pool that enables clinical trials of a scale and speed difficult to match elsewhere. FAVOR III China enrolled 3,847 patients at 26 sites in just 18 months. REC-CAGEFREE I, another recent Chinese trial published in The Lancet in 2024, randomized 2,272 patients at 43 sites testing drug-coated balloon angioplasty versus drug-eluting stents for de novo coronary lesions — a trial that would have taken twice as long in most Western countries.

The institutional core of this research ecosystem is Fuwai Hospital in Beijing, the National Center for Cardiovascular Diseases of China. Fuwai performs more than 40,000 PCI procedures annually — more than any single center in the world by a substantial margin. Its catheterization laboratory complex has over 20 rooms operating simultaneously. The hospital is home to the National Clinical Research Center for Cardiovascular Diseases and the State Key Laboratory of Cardiovascular Disease.

But the broader network is equally impressive. China now has more than 1,800 hospitals capable of performing PCI, and an estimated 1.6 million PCI procedures are performed annually — the largest volume of any country. This network has been harnessed for clinical research through coordination centers at Fuwai, Xijing Hospital (Fourth Military Medical University in Xi’an), the General Hospital of Northern Theater Command in Shenyang, and other major academic institutions.

The result is a pipeline of Chinese-led cardiovascular clinical trials that now regularly appear in The Lancet, The New England Journal of Medicine, JAMA, and other top-tier journals — a dramatic shift from the era when Chinese cardiology was primarily a consumer, rather than a producer, of clinical evidence.

6. Where to Access QFR-Guided PCI: China’s Leading Heart Centers

Nurse examining medical monitor displaying vital signs

For international patients seeking coronary intervention in China, the following institutions combine QFR capability with world-class PCI volumes and English-language patient support.

Fuwai Hospital, Chinese Academy of Medical Sciences (Beijing)

Role: The birthplace of QFR. Dr. Xu Bo’s catheterization laboratory is where the technology was developed and validated. Fuwai performs over 40,000 PCI procedures annually and has an International Medical Center with English-speaking cardiologists. The hospital is the coordinating center for most major Chinese PCI trials.

  • Annual PCI volume: ~40,000+
  • Key physicians: Dr. Xu Bo (徐波), Dr. Gao Runlin (高润霖, Academician), Dr. Yang Yuejin (杨跃进)

Xijing Hospital, Fourth Military Medical University (Xi’an)

Role: Led by Dr. Tao Ling, Xijing Hospital was the coordinating center for the REC-CAGEFREE I trial and is one of China’s premier interventional cardiology centers. The hospital has extensive experience with both QFR-guided PCI and drug-coated balloon angioplasty.

  • Annual PCI volume: ~15,000
  • Key physicians: Dr. Tao Ling (陶凌), Dr. Gao Chao (高超)

General Hospital of Northern Theater Command (Shenyang)

Role: Led by Academician Dr. Han Yaling (韩雅玲), one of China’s most distinguished female cardiologists, this center has led multiple landmark trials including BRIGHT, I-LOVE-IT 2, and participated in FAVOR III China. Dr. Han is a member of the Chinese Academy of Engineering.

  • Annual PCI volume: ~8,000
  • Key physicians: Dr. Han Yaling (韩雅玲, Academician), Dr. Wang Xiaozeng (王效增)

Zhongshan Hospital, Fudan University (Shanghai)

Role: Led by Academician Dr. Ge Junbo (葛均波), a pioneer of Chinese interventional cardiology who performed China’s first TAVR procedure. Zhongshan Hospital is a national center for complex coronary intervention and structural heart disease.

  • Annual PCI volume: ~15,000
  • Key physicians: Dr. Ge Junbo (葛均波, Academician), Dr. Qian Juying (钱菊英)

Other Notable Centers

  • West China Hospital, Sichuan University (Chengdu) — one of China’s largest PCI centers, with robust international patient services
  • The Second Xiangya Hospital, Central South University (Changsha) — major research center and QFR adopter
  • Renmin Hospital of Wuhan University (Wuhan) — key site in multiple landmark trials
  • Guangdong Provincial People’s Hospital (Guangzhou) — leading southern China center
  • Anzhen Hospital, Capital Medical University (Beijing) — second only to Fuwai in Beijing PCI volume

7. From Lab Bench to Global Market: The QFR Commercialization Story

Medical stethoscope in a clinical setting

The story of QFR is not only a scientific one but also a commercial one — and it illustrates China’s growing ability to translate homegrown medical innovations into globally competitive products.

The QFR software was commercialized through Pulse Medical Imaging Technology (Shanghai) Co., Ltd. (搏动医学影像), a Shanghai-based medical device company founded in 2015. The QFR system received China’s National Medical Products Administration (NMPA) approval in 2018, making it the first angiography-based FFR system approved anywhere in the world. CE Mark approval for the European market followed in 2020.

The commercial product is marketed as AngioPlus — a software-only system that integrates with existing angiographic X-ray equipment from all major manufacturers (Siemens, Philips, GE, Canon). Because QFR requires no additional hardware, the capital cost for a hospital is limited to the software license and a dedicated workstation, making it accessible to hospitals that could never afford a full FFR wire program.

As of 2026, AngioPlus is deployed in over 500 hospitals in China and has been adopted by centers in Europe, Japan, Southeast Asia, and the Middle East. The company has raised multiple rounds of venture funding and is preparing regulatory submissions for the U.S. FDA.

The broader Chinese cardiovascular device industry has followed a similar trajectory. Other notable homegrown innovations include:

  • Firesorb Bioresorbable Scaffold (MicroPort) — an ultra-thin (100–125 μm strut thickness) sirolimus-eluting bioresorbable scaffold that dissolves completely within 2–3 years, leaving no permanent implant. Clinical trials (FUTURE-I, FUTURE-II) have shown excellent results.
  • VenusA-Valve (Venus MedTech) — China’s first domestically developed transcatheter aortic valve replacement (TAVR) device, now implanted in thousands of patients.
  • VitaFlow TAVR System (MicroPort) — a second-generation TAVR valve with a motorized delivery system, designed for superior ease of use.

8. Beyond QFR: China’s Other Landmark Cardiovascular Trials, 2023–2026

Radiologist analyzing medical scans on computer monitors

QFR is the flagship, but it sails in a fleet. Chinese cardiology has produced a series of landmark randomized trials over the past three years that have reshaped international practice guidelines:

REC-CAGEFREE I (The Lancet, 2024)

This 2,272-patient trial at 43 Chinese sites asked a provocative question: can a drug-coated balloon (DCB) with rescue stenting replace planned drug-eluting stent (DES) implantation for de novo coronary lesions? The primary endpoint was device-oriented composite events (DoCE) at 24 months. The result: DCB did not achieve non-inferiority (6.4% vs. 3.4%, pnon-inferiority = 0.65), confirming that DES remains the preferred strategy. Though technically a “negative” trial, REC-CAGEFREE I provided the definitive answer to a question that had divided interventional cardiologists for years, and was hailed as a model of rigorous clinical investigation.

BRIGHT-4 (JAMA, 2023)

Led by Dr. Han Yaling at the General Hospital of Northern Theater Command, this 6,016-patient trial compared bivalirudin plus a post-PCI high-dose infusion versus heparin monotherapy in patients with ST-elevation myocardial infarction (STEMI). Bivalirudin significantly reduced the 30-day rate of net adverse clinical events, driven by a large reduction in major bleeding, without an increase in stent thrombosis or ischemic events. The trial established a new standard for anticoagulation in primary PCI.

ULTIMATE-DAPT (The Lancet, 2024)

A 3,400-patient Chinese trial led by Dr. Zhang Zheng and colleagues, ULTIMATE-DAPT tested whether ticagrelor monotherapy after one month of dual antiplatelet therapy (DAPT) was superior to continued DAPT for 12 months after PCI. Ticagrelor monotherapy significantly reduced clinically relevant bleeding (2.1% vs. 4.6%) while maintaining non-inferiority for ischemic events. The trial contributed to the growing evidence base supporting abbreviated DAPT strategies — a global trend that Chinese investigators have been at the forefront of documenting.

YearTrialNFindingJournal
2023BRIGHT-46,016Bivalirudin + infusion superior to heparin for STEMIJAMA
2024ULTIMATE-DAPT3,400Ticagrelor monotherapy after 1-month DAPT reduces bleedingLancet
2024REC-CAGEFREE I2,272DCB non-inferior to DES not met; DES remains standardLancet
2024FAVOR III China (3-yr)3,847QFR-guided PCI benefit sustained at 3 yearsPresented

9. What This Means for International Heart Patients

Doctor reviewing medical diagnostics on multiple monitors

For the international patient considering cardiac care in China, the QFR era brings several concrete advantages:

Evidence-Based Decision-Making

The single greatest risk in PCI is the wrong decision: stenting a lesion that doesn’t need it, or leaving a lesion that does. QFR removes subjectivity from this decision. International patients at QFR-equipped Chinese centers receive a physiology-guided assessment that meets the highest international standards of care.

Cost Advantage

In the United States, a single PCI procedure costs US$20,000–50,000 on average. In China, the cost for a standard PCI at a top-tier hospital ranges from approximately RMB 30,000–80,000 (US$4,100–11,000), including the stent, hospitalization, and QFR assessment. The cost differential is even larger for complex procedures: TAVR, which costs US$150,000+ in the U.S., can be performed in China for approximately US$40,000–60,000.

Volume Equals Expertise

Chinese interventional cardiologists at major centers perform PCI volume that few Western cardiologists can match. A senior operator at Fuwai Hospital may perform 1,000+ PCIs per year, including the most complex chronic total occlusion (CTO) cases, left main bifurcations, and multi-vessel disease. This volume translates into technical proficiency, particularly for complex anatomies that lower-volume operators might refer to surgery.

Technology Access

Chinese hospitals are among the earliest adopters of new cardiovascular technologies, partly because China is now a developer, not just a consumer. QFR, Firesorb BRS, domestic TAVR valves, and robotic PCI systems are often available in China before they reach Western markets.

Practical Considerations

  • Language: Fuwai Hospital, Anzhen Hospital, and Zhongshan Hospital have international patient centers with English-speaking staff. Smaller centers may require a translator.
  • Cost: elective PCI at a top Chinese center: approximately RMB 30,000–80,000 (US$4,100–11,000), compared to US$20,000–50,000 in the United States.
  • Wait times: non-emergency PCI at a major center can typically be scheduled within 1–2 weeks of initial consultation.
  • Visa: Medical treatment visas (M or S2) are available. Many nationalities also qualify for China’s 30-day unilateral visa-free policy or 240-hour transit visa-free policy. Consult the Chinese embassy or consulate in your country for current requirements.

Sources and References

This article is for informational purposes only and does not constitute medical advice. Patients should consult qualified healthcare professionals for personalized medical guidance.

← Back to News